NO20070779L - Farmasoytiske doseringsformer omfattende et lavt-loselig medikament og en polymer - Google Patents

Farmasoytiske doseringsformer omfattende et lavt-loselig medikament og en polymer

Info

Publication number
NO20070779L
NO20070779L NO20070779A NO20070779A NO20070779L NO 20070779 L NO20070779 L NO 20070779L NO 20070779 A NO20070779 A NO 20070779A NO 20070779 A NO20070779 A NO 20070779A NO 20070779 L NO20070779 L NO 20070779L
Authority
NO
Norway
Prior art keywords
low
polymer
dosage forms
pharmaceutical dosage
soluble drug
Prior art date
Application number
NO20070779A
Other languages
English (en)
Inventor
Ravi Mysore Shanker
Sheri Lynn Shamblin
Leah Elisabeth Appel
Walter Christian Babcock
Dwayne Thomas Friesen
Roderick Jack Ray
Daniel Tod Smithey
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20070779L publication Critical patent/NO20070779L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives en doseringsform omfattende et lavløselighetsmedikament, og en presipiteringsinhiberende polymer. Medikamentet er i en løselighetsforbedret form og i form av partikler som er minst part ielt belagt med den presipiteringsinhiberende polymer. Representative lavløselighetsmedikamenter er ziprasidon og sildenafil. Representativ presipiteringsinhiberende polymer er HPMCAS.
NO20070779A 2004-08-31 2007-02-09 Farmasoytiske doseringsformer omfattende et lavt-loselig medikament og en polymer NO20070779L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60617804P 2004-08-31 2004-08-31
PCT/IB2005/002704 WO2006024944A2 (en) 2004-08-31 2005-08-18 Pharmaceutical dosage forms comprising a low-solubility drug and a polymer

Publications (1)

Publication Number Publication Date
NO20070779L true NO20070779L (no) 2007-03-08

Family

ID=35705238

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070779A NO20070779L (no) 2004-08-31 2007-02-09 Farmasoytiske doseringsformer omfattende et lavt-loselig medikament og en polymer

Country Status (14)

Country Link
US (2) US20090142404A1 (no)
EP (1) EP1789020A2 (no)
JP (1) JP2008511607A (no)
KR (1) KR20070046892A (no)
CN (1) CN101123951A (no)
AU (1) AU2005278894A1 (no)
BR (1) BRPI0514753A (no)
CA (1) CA2577852A1 (no)
IL (1) IL181197A0 (no)
MX (1) MX2007002378A (no)
NO (1) NO20070779L (no)
RU (1) RU2007106036A (no)
WO (1) WO2006024944A2 (no)
ZA (1) ZA200701059B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024944A2 (en) 2004-08-31 2006-03-09 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
WO2010146407A1 (en) * 2009-06-19 2010-12-23 Nanoform Hungary Ltd. Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
CN102139115B (zh) * 2011-03-30 2012-12-05 天津红日药业股份有限公司 阿托伐他汀的环糊精包合物及其口服固体制剂的制备方法
EP3212169B1 (en) 2014-10-31 2021-01-13 Bend Research, Inc. Process for forming active domains dispersed in a matrix
CN107303278B (zh) * 2016-04-25 2020-11-13 成都海创药业有限公司 一种hc-1119固体分散体及其制备方法
TWI631985B (zh) * 2016-10-26 2018-08-11 財團法人金屬工業研究發展中心 微粒製造方法
US20210251985A1 (en) * 2017-12-26 2021-08-19 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof
ES2967689T3 (es) 2018-04-06 2024-05-03 Capsugel Belgium Nv Proceso de secado por aspersión para partículas de baja relación de aspecto que comprenden poli[(metacrilato de metilo)-co-(ácido metacrílico)]
CN111728953B (zh) * 2020-07-29 2023-08-08 中国科学院上海药物研究所 一种托法替布或其盐的缓释制剂及其制备方法
WO2022081310A2 (en) * 2020-09-22 2022-04-21 Michael Ogburn Inhaled pde-v inhibitor drugs

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5277916A (en) * 1988-02-01 1994-01-11 F. H. Faulding & Co., Ltd. Tetracycline dosage form
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
ES2306646T3 (es) * 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
DE60039802D1 (de) * 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
HUP0204372A3 (en) * 1999-12-23 2004-06-28 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
US7125565B2 (en) * 2000-12-01 2006-10-24 Kyowa Hakko Kogyo Co., Ltd. Composition improved in the solubility or oral absorbability
ATE486586T1 (de) * 2001-06-22 2010-11-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
JP2005523262A (ja) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
AU2003249474A1 (en) * 2002-08-12 2004-02-25 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
KR20060115350A (ko) * 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
AU2004294818A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations
CA2551254A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
WO2006024944A2 (en) 2004-08-31 2006-03-09 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
MX2009011681A (es) * 2007-05-18 2009-11-10 Scidose Llc Formulaciones de ziprasidona.

Also Published As

Publication number Publication date
WO2006024944A3 (en) 2006-08-24
ZA200701059B (en) 2008-08-27
MX2007002378A (es) 2007-04-23
RU2007106036A (ru) 2008-10-10
CA2577852A1 (en) 2006-03-09
BRPI0514753A (pt) 2008-06-24
EP1789020A2 (en) 2007-05-30
CN101123951A (zh) 2008-02-13
JP2008511607A (ja) 2008-04-17
US20150064264A1 (en) 2015-03-05
WO2006024944A2 (en) 2006-03-09
US20090142404A1 (en) 2009-06-04
KR20070046892A (ko) 2007-05-03
US9445998B2 (en) 2016-09-20
IL181197A0 (en) 2007-07-04
AU2005278894A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
NO20070779L (no) Farmasoytiske doseringsformer omfattende et lavt-loselig medikament og en polymer
NO20065878L (no) Terapeutiske forbindelser
LU93321I2 (fr) Ibrutinib, ou un sel pharmaceutiquement acceptable de celui-ci
EA201100958A1 (ru) Фармацевтическая пероральная дозированная лекарственная форма на основе ингибиторов dpp iv
NO20072931L (no) Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva
LTC1765293I2 (lt) Farmacinės kompozicijos vaistų pristatymui ir būklių gydymo arba prevencijos būdai naudojant tas kompozicijas
DE602005026395D1 (de) Neue zyklische harnstoffderivate, deren herstellung und pharmazeutische verwendung damit als kinase-inhibitoren
WO2007126964A3 (en) Kinase inhibitors
RS53891B1 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING OXYCODON HYDROCHLORIDE WITH LESS THAN 25 PPM 14-HYDROXYCODEINONE
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
WO2006060547A3 (en) Systems and methods for intra-oral drug delivery
NO20071751L (no) Fremgangsmater og kit for levering av legemidler ved nebulisering
NO20061662L (no) Farmasoytisk preparat omfattende en P2X7 reseptorantagonisk og ikke-steroid intiinfammatorisk medikament
DE60315892D1 (de) Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
SI2046775T1 (sl) Derivati N-(amino-heteroaril)-1H-indol-2-karboksamidov kot antagonisti receptorjev tipa TRPV1 ali VR1
EA200701159A1 (ru) Комбинированное лекарственное средство, включающее телмисартан и гидрохлортиазид
ATE468846T1 (de) Magenresistente pharmazeutische dosierform mit n- (2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d- glutaminsäure (lk-423)
FR2873691B1 (fr) Derives d'amino-piperidine, leur preparation et leur application en therapeutique
ATE538125T1 (de) Neue 2-azaindol-derivate, deren herstellung und pharmazeutische verwendung als kinase-inhibitoren
TW200628458A (en) Metasubstituted thiazolidinones, their manufacture and use as a drug
NO20071806L (no) Tabletter med steds- og tidsregulert gastrointestinal frigivelse av aktiv bestanddel.
DE602005011818D1 (de) Aminotropanderivate, deren herstellung und deren therapeutische verwendung
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
NO20073023L (no) Forhindring av vertikal endoparasitt infeksjoner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application